Opinion|Videos|October 11, 2024

Meningococcal Infection and NMOSD

Key Takeaways

  • Eculizumab and ravulizumab increase meningococcal infection risk, necessitating vaccination in treated patients.
  • Phase 3 and long-term studies emphasize the need for vigilant monitoring and prophylactic measures despite vaccination.
SHOW MORE

Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.

Episodes in this series

Video content above is prompted by the following:

  1. Discuss the risk of meningococcal infection with eculizumab and ravulizumab in phase 3 and long-term extension studies.
  2. There may be concerns with meningococcal vaccination and its impact on relapse activity. What is your interpretation of these data?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!